Drug Development Executive

Eswar Krishnan, MD
  • 0.0（0）
  • 科学
  • アップデート：毎週

Welcome to our podcast, designed specifically for biotech executives passionate about drug development. Join us as we explore a wide range of engaging topics, from cutting-edge advancements in translational sciences to the latest regulatory updates. Let’s navigate this dynamic landscape together and stay ahead of the curve! www.drugdevelop.com

エピソード

  1. State Of The Art in SLE: For Biotech CMOs and CSOs

    2025/07/18

    State Of The Art in SLE: For Biotech CMOs and CSOs

    This podcast summarizes the therapeutic landscape and the underlying molecular understanding of the causal pathways in lupus. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com/subscribe

    46分

  2. 2025/07/14

    mAbs vs CAR-T: A Head-to-Head Comparison for CMOs and CSOs

    CAR-T Illustration. Courtesy New Scientist A recent head-to-head study assessed the comparative effectiveness of different B-cell depletion strategies in patients with autoimmune diseases, specifically comparing protein-based therapies like obinutuzumab (OBI), blinatumomab (BLI), and rituximab (RTX) with cell-based CD19 chimeric antigen receptor (CAR) T-cell therapy. Researchers analyzed lymph node biopsies to assess the extent of B-cell depletion and changes in follicular architecture. They documented that CAR-T was most effective in depleting B cells and disrupting follicular architecture, and concluded that these data indicate potential superiority of CAR-T cell therapies. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com/subscribe

    30分

  3. 2025/07/07

    Type 5 Diabetes: For CMOs and CSOs

    This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com/subscribe

    6分

  4. 2025/07/06

    B-cell depletion for autoimmune diseases: For Biotech CMOs and CSOs

    New B cell depleters in development may offer superior impact on the immune system, durably "reset" the immune system, potentially cure conditions like pre-Type 1 Diabetes and SLE, or allow celiac disease patients to tolerate gluten again. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com/subscribe

    17分

  5. 2025/07/03

    Interleukin-6 and Cardioimmunology: For CMOs and CSOs

    This podcast discusses the role of inflammation, specifically interleukin-6 (IL-6) signaling, in cardiovascular diseases (CVD), including atherosclerosis and myocardial infarction (MI). We discuss the therapeutic potential of blocking IL-6 or its receptor (IL-6R) with drugs like tocilizumab and ziltivekimab, highlighting their ability to reduce inflammatory markers, such as C-reactive protein (CRP), and potentially improve patient outcomes in conditions like ST-elevation myocardial infarction (STEMI) and rheumatoid arthritis (RA). The "ZEUS trial" is presented as a significant ongoing study evaluating ziltivekimab's impact on major adverse cardiovascular events in high-risk patients. The podcast balances the potential benefits of these treatments with the complexities and potential side effects of anti-inflammatory therapies, such as an increased risk of infection or gastrointestinal perforation, emphasizing the need for further research and personalized treatment approaches. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com/subscribe

    16分
  6. CAR T-Cell Therapy trials in Lupus just got a bit easier: For Biotech CMOs and CSOs

    2025/06/29

    CAR T-Cell Therapy trials in Lupus just got a bit easier: For Biotech CMOs and CSOs

    This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com/subscribe

    48分
  7. Fast Approvals with FDA's Voucher Programs: For Biotech CMOs and CSOs

    2025/06/29

    Fast Approvals with FDA's Voucher Programs: For Biotech CMOs and CSOs

    This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com/subscribe

    32分

  8. 2025/06/24

    Digital Twins For Biotech CMOs and CSOs

    This is an audio companion to the blog post in Substack This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com/subscribe

    41分
  9. Digital Twins for CSOs and CMOs

    2025/06/21

    Digital Twins for CSOs and CMOs

    This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com/subscribe

    41分
  10. FDAs Recent Roundtable on Cell and Gene Therapies

    2025/06/08

    FDAs Recent Roundtable on Cell and Gene Therapies

    This podcast summarizes the FDA roundtable conducted on June 6, 2025. The original source is provided here This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com/subscribe

    18分
  • 10話のエピソード

番組について

Welcome to our podcast, designed specifically for biotech executives passionate about drug development. Join us as we explore a wide range of engaging topics, from cutting-edge advancements in translational sciences to the latest regulatory updates. Let’s navigate this dynamic landscape together and stay ahead of the curve! www.drugdevelop.com

情報

  • クリエイター
    Eswar Krishnan, MD
  • 配信期間
    25年
  • エピソード
    10
  • 制限指定
    不適切な内容を含まない
  • Copyright
    © Eswar Krishnan
  • 番組のWebサイト
    Drug Development Executive